Vanda Pharmaceuticals Inc. (VNDA) Hits New 52-week Low During February 09 Session

Equities Staff |

Vanda Pharmaceuticals Inc. (VNDA) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $7.85, Vanda Pharmaceuticals Inc. dropped to $7.73 for a new 52-week low. By the closing bell, the company's stock was at $8.14 a share for a gain of 1.5%.

Falling to a new 52-week low is never fun for company's shareholder, but, depending on who you ask, it can be either a buy or a sell signal. Someone bearish on the stock might see it reaching its lowest price in a year as a sign of growing downward momentum and make sure they sell their shares. Bulls, though, are more likely to see a new 52-week low as the stock hitting its low point and anticipate a bounce in the share price.

However one plays it, it's often a critical moment for any stock and should be noted by investors.

Vanda Pharmaceuticals Inc. saw 351,552 shares of its stock trade hands, that's out of 42.82 million shares outstand. The stock has an average daily volume of 746,130 shares. After hitting a new 52-week low, Vanda Pharmaceuticals Inc. enters the new trading day with a market cap of 348.52 million, a 50-day SMA of $9.00 and a 200-day SMA of $10.82

Vanda Pharmaceuticals Inc. now has a P/E ratio of 6.8.

For a complete fundamental analysis analysis of Vanda Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for VNDA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders such as HETLIOZ, Fanapt and VLY-686.

Vanda Pharmaceuticals Inc. has 64 employees, is led by CEO Mihael Hristos Polymeropoulos, and makes its home in Washington, DC.

Vanda Pharmaceuticals Inc. is also a component of the Russell 2000 Index, which is generally viewed as the most reliable indicator of the health of the broader small-cap market. Using a rules-based methodology, it creates a simple, unbiased view of how America's stable of smaller publicly traded companies are performing in the stock markets.

The index consists of the 2,000 smallest companies of the 3,000 largest publicly-traded companies in the country as judged by market cap. It's constructed by Russell Investments, which also builds and maintains the Russell 3000 (an index consisting of all 3,000 biggest companies by market cap) and the large-cap Russell 1000 (which has the 1,000 largest companies from the Russell 3000).

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…

Almond Smart Home Router by Securifi

Securifi sells user friendly touch screen routers that also have support for IoT/home automation.Securifi’s Almond revolutionized wireless router setup with its easy to use Touchscreen Interface in 2012. Now our…